Melanoma of unknown primary: New perspectives for an old story.
Diagnosis
Immunotherapy
Incidence
Melanoma of unknown primary
Prognostic factors
Survival
Targeted therapy
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
20
08
2020
revised:
28
11
2020
accepted:
20
12
2020
pubmed:
1
1
2021
medline:
16
2
2021
entrez:
31
12
2020
Statut:
ppublish
Résumé
Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or BRAF/MEK inhibitors found improved survival in favor of MUP, whereas others reported equivalent or poorer outcomes. Here, we discuss the genetic and molecular features, epidemiology, diagnosis, prognostic factors, survival, and treatment of MUP in comparison with MKP, in the pre- and post-novel therapy era.
Identifiants
pubmed: 33383207
pii: S1040-8428(20)30344-9
doi: 10.1016/j.critrevonc.2020.103208
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103208Informations de copyright
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.